{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121099","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.439969+00:00","generated_at":"2026-05-30T05:25:27.002751+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beam reports initial BEAM-101 clinical data: engraftment, HbF >60%, one death from busulfan conditioning","bullets":["BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.","BEAM-101: One death from respiratory failure attributed to busulfan conditioning, not BEAM-101; DSMC and FDA reviewed.","BEAM-201 (T-ALL/T-LL): 2 of 3 patients achieved CRi/CR at doses <200 million cells; both eligible for stem cell transplant.","ESCAPE NHP data: CD117 mAb conditioning well tolerated; HbF reached ~85% F-cells by 35 weeks in both animals.","Initial data from BEACON trial also showed no VOCs post-treatment and normalization of hemolysis markers in all 4 evaluable patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121099","json":"https://secwatch.observer/filing/0000950170-24-121099.json","markdown":"https://secwatch.observer/filing/0000950170-24-121099.md","text":"https://secwatch.observer/filing/0000950170-24-121099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024121099/0000950170-24-121099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017024121099/beam-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:25:27.002751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}